BRISBANE, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced that the Company's compensation committee granted five new employees a total of 14,300 shares of common stock options effective on October 28, 2016. The common stock options were granted pursuant to the Company's 2016 Inducement Equity Incentive Plan. The awards were made pursuant to the NASDAQ Global Market's inducement grant exception as a component of our new hires' employment compensation. The new employees receiving the options recently joined the Company. These options vest over four years with 25% of the options vesting on the first anniversary of each employee's respective vesting commencement date, and 1/48 th of the total grant vesting monthly thereafter, subject to continued service through each applicable vesting date. Each of the employees who received an equity award is a non-executive employee. About CareDxCareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. The Company markets AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection. CareDx is pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure™, a next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP® is a set of HLA typing tools used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation. Olerup QTYPE® offers speed and precision in real time as a rapid HLA typing tool. XM-ONE® is the first standardized test that quickly identifies a patient's antigens against HLA Class I, Class II or antibodies against a donor's endothelium. For more information, please visit: www.CareDx.com.
Investor Contact Jamar Ismail, Westwicke PartnersT: +1 firstname.lastname@example.org